



Osteoporosis Clinical Practice Guidelines

Definition

The world health organization WHO defines osteoporosis as a systemic skeletal disease characterized by low bone mass and micro -architectural deterioration of bone tissue with a resultant increase in fragility and risk of fracture

Assessment (History and Examination)

Initial Evaluation for Osteoporosis

All postmenopausal women age ≥50 years of age should undergo clinical assessment for osteoporosis and a detailed history, physical exam, and clinical fracture risk assessment with Fracture Risk Assessment tool (FRAX®) Note: FRAX age 40-90, Saudi FRAX in process of endorsement. Use USA white as per Saudi Osteoporosis Society SOS1).Or the Kuwaiti FRAX (similar hip fracture incidence to Saudi Arabia) until the Saudi FRAX is available

History	Exam
 Prior osteoporosis-related fractures 	•Height loss (>2cm prospectively)
•Prolonged steroid use	•Weight (BMI)
•Height loss > 6 cm historically	•Low <60 Kg
•Current smoking	•Major loss (≥10% of weight since age 25)
•Excess alcohol≥ 3 units per day	•Kyphosis
•Parental hip fracture	•Rib to pelvis distance >2 FBs
•Falls in past 12 months	•Balance and gait, "Get up and Go" Test
•Other high-risk conditions or medications	
EDAY Clinical risk factors in EDAY®	

FRAX Clinical risk factors in FRAX®

www.shef.ac.uk/FRAX

- •age
- •Sex
- •body mass index (BMI)
- •smoking, alcohol use
- prior fracture
- •parental history of hip fracture
- •use of glucocorticoids
- •rheumatoid arthritis
- secondary osteoporosis

femoral neck BMD














Current smoking

High alcohol intake

PPI and anticonvulsant)

or radiological finding)

prednisone-equivalent dose ≥ 7.5mg daily

Low body weight (< 60 kg) or major weight loss (>10% of weight at age 25 years)

Other high-risk medication use (tamoxifen, thiazolidinedione, Empagliflozin,

 X-ray findings suggestive of osteoporosis such as vertebral fracture, osteopenia identified on X-ray, fragility fracture, loss of height, or thoracic kyphosis (clinical

- Rheumatoid arthritis
- Other disorders strongly associated with osteoporosis such as primary hyperparathyroidism, type 1 diabetes, osteogenesis imperfecta, uncontrolled hyperthyroidism, Cushing's, disease, chronic malnutrition or malabsorption, chronic inflammatory conditions (e.g., inflammatory bowel disease)

2020 AACE American Association of Clinical Endocrinologists Diagnosis of Osteoporosis in Postmenopausal Women (2)

- 1. T-score -2.5 or below in the lumbar spine, femoral neck, total proximal femur, or 1/3 radius
- 2. Low-trauma spine or hip fracture (regardless of bone mineral density)
- 3. T-score between -1.0 and -2.5 and a fragility fracture of proximal humerus, pelvis, or distal forearm
- 4. T-score between −1.0 and −2.5 and high FRAX® (or if available, TBS-adjusted FRAX®) 10-year probability for major osteoporotic fracture is ≥20% or the 10-year probability of hip fracture is ≥3% FRAX® = fracture risk assessment tool; TBS = trabecular bone score

For All Osteoporotic Patient Evaluate for Causes of Secondary Osteoporosis Before Start Treatment

- Serum chemistry: TSH calcium, phosphate, total protein, albumin, liver enzymes, alkaline phosphatases, creatinine, and electrolytes.
- Serum 25-hydroxyvitamin D Complete blood cell count
- SPE serum protein electrophoresis if vertebral fracture or suspect multiple myeloma
- X-ray lateral thoracolumbar screen for vertebral fracture if not available from DXA

Recommend pharmacologic therapy Education on lifestyle measures, fall prevention, benefits, & risks of medications












Management











CALCIUM Premenopausal, men <50 years and	Instructions: Calcium should be taken with meals for better absorption. Calcium should not be taken with iron (absorption may be adversely affected when given concurrently)
pregnant women (1000 mg/d), Postmenopausal, men >50 years (1500 mg/d)	Caution in patient with hypercalcemia and patients with history of renal stones
Premenopausal, men <50 yr and pregnant women (600 IU/d) Postmenopausal, men >50 yr (1000 IU/d)	Instructions: Expose to sun for 10-15 min 2-3 times/wk Caution in patient with hypercalcemia and patients with history of renal stones
ALENDRONATE	Instructions: should be taken as soon as patient wakes up in the morning, before eating, or drinking anything.
70 mg once weekly	- Tablet should be swallowed as a whole with a large glass (8 ounces) of plain water only (not mineral water, coffee, juice, or any other liquid).
Antiresorptive oral	- Patient should not lie down on their back, eat, or drink for at least 30 min after taking alendronate.
Consider drug holiday after 5 years	SE:1) Hypocalcemia 2) atypical fracture of the femur 3) osteonecrosis of the jaw defer initiation or hold if Invasive dental procedures Contraindicated:
	1) Should not be prescribed for patients with active esophageal abnormalities or peptic ulcer disease. And inability to remain upright for at least % hour after the dose
zoledronate	2) In pregnancy, women who plan to be pregnant. 3) In patients with creatinine clearance below 30 mL/min. One infusion per year over minimum of 15 min. Good hydration before receiving the medication.
5 mg IV once yearly	Correct hypocalcemia before starting treatment.
Antiresorptive Intravenous	SE: Hypersensitivity, flu-like reaction, Risk of atypical fracture, ONJ, Arterial fibrillation Contraindicated: in pregnancy, women who plan to be pregnant, and in patients with creatinine clearance below 30 mL/min
Consider drug holiday after 3 years	
Denosumab (Prolia)	60 mg denosumab in 1 mL solution in a single-use prefilled syringe or vial Subcutaneous injection every 6 months
60 mg SC every 6 months Antiresorptive SC injection	SE: Eczema, cellulitis, low calcium
	Contraindicated:
	1) In pregnancy, women who plan to be pregnant. 2) Risk of atypical fracture, ONJ, Dose adjustment for renal impairment is not necessary. CrCl > 30 ml/min
DAI OVICEN	risk of sever hypocalcemia if CrCl <30 ml/min
60 mg/d oral	SE: premenopausal women worsening of hot flashes, leg cramps, increase risk of deep vein thrombosis.
SERMS (Evista)	Increased risk of thromboembolic events Risks needs to be weighed against benefits, especially in patients with or at risk of CHD (in whom treatment radiuses workship) fractures and breast cancer risk at the same absolute rate that it increases the VTF and fatal stroke risk)











Recommend: Education on lifestyle measures, fall prevention, benefits and risks of medications

Exercise type /benefits	Frequency	Comment
Posture exercises keep you standing tall, not stooped.	Daily 10 mint	Pay attention to your posture posture when you stand and sit, do back exercises that extend your spine.
Balance exercises help you be more stable on your feet. You can walk more easily. Good balance helps prevent falls.	Daily 20 mint	walk heel to toe, reduce base of support, shift your weight, respond to things that upset your balance.
Strength exercises keep you strong and fit.	2 times per week	Exercise for leg ,arm ,chest shoulder and back. Use body weight against gravity ,band and weights *
Aerobic physical activity (moderate to vigorous intensity) improves your overall health. It can reduce your risk of disease. It may improve your bone strength.	150 minutes per week	Do aerobic physical activity for about 20 to 30 minutes per day. Exercise for at least 10 minutes at a time. In total, do 150 minutes or more per week.* If you are new to exercise or if you have had a spine fracture, start at low to moderate intensity — 3 to 6 on the scale*

^{*}Refer to physical therapy for advice for proper exercise for each patient

Give patient medication card when starting the treatment this is essential for collaborative medical care between specialist and primary care example: Abaloparatide or Teriparatide taken once in life time for up to 2 years and need to be followed by antiresorptive treatment. Moreover, it is essential to know when the patient can go for drug holiday.

Medication:		
Calcium: Dietary sources:	mg Supplements:	mg
Vitamin D:		
Exercise:	_ minutes daily / weekly	
Fall Prevention advice		
Follow up DXA / labs in	months. Return visit in	_ months









R3 Osteoporosis Screening Pathway: Screening Continuous patient support (virtual and clinical when necessary) and monitoring (at home or care facility) Patient is planned for check up or is referred to PHC for any other health condition No 1° care Primary care physician to assess medical history and conduct a physical exam Fracture ' DEXA scan Yes Yes $\overline{\checkmark}$ 2° care Patient presenting with a fracture Manage fracture DEXA scan Refer to endocrinologist or rheumatologist and start treatment 3° or 4° care "Women aged ≥ 65 years and men aged ≥ 75 years or women aged < 65 years and men aged < 75 years with one of the following: previous fragility fracture, use of oral or systemic glucocorticoids, history of falls, family history of hip fracture, BMI < 18.5 kg/m2, smoking. Mawid









APPROVL					
	Name:	Position:	Signature:		
Prepared By:	Dr. Ahmed Al Zahrani Dr. Ahlam Al Harbi	FM Consultants			
Reviewed and Approved By:	Dr. Mansoor Allajhar Dr. Musa Althwayee Dr. Ahmed Al Zahrani Dr. Hajar Al Suma Dr. Ahlam Al Harbi	FM Consultants			

Reference

2015 Guidelines for Osteoporosis in Saudi Arabia: Recommendations from the Saudi Osteoporosis Society Ann Saudi Med 2015,35(1):1-12

- 1. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/ AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS 2020 UPDATE Endor Pract. 2020;26(Suppl 1)
- 2. Camacho et al. Endoer Pract. 2020.26.564-570
- 3. Shoback et al. J Clin Endocrinol Metab, 2020, 105(3), 1-8
- 4. Eastell et al. J Clin Endocrinol Metab. 2019, 104, 1595-1622
- 5. Kanis et al. Osteoporosis Int. 2020, 31, 1-12



